Gilead Sciences (NASDAQ:GILD) Now Covered by Scotiabank

Scotiabank started coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued on Thursday, MarketBeat.com reports. The brokerage set a “sector outperform” rating and a $140.00 price target on the biopharmaceutical company’s stock. Scotiabank’s price target suggests a potential upside of 10.19% from the company’s previous close.

GILD has been the subject of a number of other reports. Morgan Stanley lifted their price target on shares of Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Citigroup boosted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Finally, TD Cowen upped their target price on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $128.83.

Gilead Sciences Trading Up 3.0%

Shares of GILD traded up $3.66 during trading hours on Thursday, reaching $127.06. 666,259 shares of the company traded hands, compared to its average volume of 7,930,118. The company’s fifty day moving average price is $116.99 and its two-hundred day moving average price is $112.55. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $157.64 billion, a price-to-earnings ratio of 25.33, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Gilead Sciences has a 12 month low of $86.08 and a 12 month high of $126.51.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. This represents a 2.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 71,500 shares of company stock worth $8,336,040 in the last quarter. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Activest Wealth Management boosted its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC raised its stake in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new position in shares of Gilead Sciences in the third quarter valued at $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the 2nd quarter worth approximately $27,000. Finally, Putney Financial Group LLC boosted its holdings in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.